{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:55:15Z","timestamp":1788897315633,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T00:00:00Z","timestamp":1032393600000},"content-version":"vor","delay-in-days":80,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2002,7]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> Skeletal morbidity is a major problem in multiple myeloma. Histomorphometric studies have demonstrated that increased bone resorption can be present even in the absence of radiographic abnormalities. To overcome diagnostic problems in estimating the activity of bone resorption, new laboratory parameters that reflect bone metabolism accurately are urgently needed. We analyzed three parameters of osteoclastic bone destruction, i.e. deoxypyridinoline (Dpd) and amino\u2010terminal collagen type\u2010I telopeptide (NTx) in urine and carboxy\u2010terminal telopeptide of type\u2010I collagen (ICTP) in serum, of 75 patients with multiple myeloma (<jats:italic>n<\/jats:italic>\u2003=\u200357) or monoclonal gammopathy of undetermined significance (MGUS, <jats:italic>n<\/jats:italic>\u2003=\u200318) by ELISA\/RIA techniques. Serum ICTP and urinary Dpd levels increased parallel to the stage of the disease and differed significantly (<jats:italic>P\u2003&lt;<\/jats:italic>\u20030.001 for ICTP and <jats:italic>P\u2003=<\/jats:italic>\u20030.03 for Dpd) between MGUS, myeloma stage I, and myeloma in stages II and III according to Salmon and Durie. ICTP and Dpd were significantly elevated in patients with multiple myeloma in stage I compared to individuals with MGUS, while no significant difference was found for NTx. In this first study comparing the prognostic relevance of ICTP, NTx, and Dpd in multiple myeloma patients, ICTP was found to be a prognostic factor for overall survival in the Kaplan\u2013Meier analysis (log\u2010rank test: <jats:italic>P\u2003&lt;<\/jats:italic>\u20030.03). Urinary NTx showed borderline significance (<jats:italic>P\u2003=<\/jats:italic>\u20030.05), and Dpd had no prognostic value in the survival analysis. Our data show that serum ICTP and urinary Dpd levels increase in parallel to advanced disease stages, and gives the first report on a significant difference in the bone resorption parameters ICTP and Dpd between individuals with MGUS and patients with myeloma in stage I. Among the bone resorption parameters studied serum ICTP was found to be the best prognostic factor for survival in multiple myeloma.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2002.00505.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:53:10Z","timestamp":1047408790000},"page":"37-42","source":"Crossref","is-referenced-by-count":57,"title":["Bone resorption parameters [carboxy\u2010terminal telopeptide of type\u2010I collagen (ICTP), amino\u2010terminal collagen type\u2010I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma"],"prefix":"10.1111","volume":"69","author":[{"given":"Christian","family":"Jakob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Zavrski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Heider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Brux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Eucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Langelotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Possinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,9,19]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"908","article-title":"Molecular therapy for multiple myeloma","volume":"86","author":"Martinelli G","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_5_3_2","first-page":"36","article-title":"Treatment of multiple myeloma","volume":"84","author":"San Miguel JF","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.353"},{"key":"e_1_2_5_5_2","first-page":"29","article-title":"Multiple myeloma. review of 869 cases","volume":"50","author":"Kyle RA","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110313251802"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07904.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762"},{"key":"e_1_2_5_9_2","first-page":"481a","article-title":"Progression of bone disease in multiple myeloma patients treated with high dose therapy and autologous stem cell transplantation","volume":"88","author":"Thornton CO","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853899309147301"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650080202"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90074.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01906.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.8672495.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3743"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/clinchem\/38.11.2313","article-title":"Bone\u2010resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared","volume":"38","author":"Bettica P","year":"1992","journal-title":"Clin Chem"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(95)00243-X"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200007010-00008"},{"key":"e_1_2_5_20_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V80.3.733.733","article-title":"C\u2010reactive protein and \u03b12\u2010microglobulin produce a simple and powerful myeloma staging system","volume":"80","author":"Bataille R","year":"1992","journal-title":"Blood"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(00)00235-0"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01960.x"},{"key":"e_1_2_5_23_2","first-page":"837","article-title":"Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells","volume":"86","author":"Sezer O","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_5_24_2","first-page":"103.","volume-title":"8th International Myeloma Workshop, Banff, Canada","author":"Facon T","year":"2001"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050170"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.00505.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.00505.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2002.00505.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T22:42:52Z","timestamp":1697496172000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2002.00505.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1034\/j.1600-0609.2002.00505.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2002.00505.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}